Abstract
Background: In the registration trial for midostaurin (RATIFY) in intensively-treated FLT3-mutated acute myeloid leukaemia (FLT3-AML), day-21 bone marrow biopsy (D21-BMB) was protocolled. Those with persistent leukaemia (PL), as defined by a morphologic blast count ≥ 5% in a cellular (> 20%) marrow received a second induction (∼25% of participants).1 However, a similar D14-BMB early response assessment strategy is known to poorly predict overall induction outcomes.2 Our study aimed to assess the predictive value of D21-BMB on induction outcomes of our local FLT3-AML population treated intensively plus midostaurin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
